AstraZeneca ((AZN)), Icon Plc ((ICLR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In a recent update, AstraZeneca and Icon Plc have announced the ongoing recruitment for their non-interventional study titled ‘A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Transthyretin (ATTR) Amyloidosis.’ The study aims to gather real-world data on patients with transthyretin amyloidosis, focusing on treatment patterns and outcomes, which is crucial for understanding this complex condition.
The study is observing the effects of treatments like eplontersen, a ligand-conjugated antisense oligonucleotide designed to silence gene activity against both mutant and wild-type TTR proteins. This approach is intended to provide insights into the effectiveness of current treatments in a real-world setting.
Designed as an observational study, it follows a cohort model with a prospective time perspective. This means researchers will collect data over time from a group of patients to understand the disease’s progression and treatment impacts without intervening directly.
The study began on May 13, 2024, with the latest update submitted on August 25, 2025. These dates are essential as they mark the study’s progress and the ongoing commitment to gathering comprehensive data.
For investors, this study could influence AstraZeneca’s and Icon Plc’s stock performance by potentially validating the effectiveness of their treatments, thus enhancing investor confidence. The study’s results may also impact the competitive landscape, as effective treatments for ATTR amyloidosis are in demand.
The study is currently recruiting, and further details can be accessed on the ClinicalTrials portal.